or
MeitY Startup Hub onboards MergerDomo to strengthen start-up ecosystem in India
Posted By - Investment Banker
Pharma company in the field of manufacturing APIs for Therapeutic drugs and Intermediates, R&D, Custom Synthesis is looking to raise funds to restart its operations. The firm has always focused on complicated chemistries and specialty products and manufactures various Therapeutic drugs including Anti-Parkinson, Anti-Ulcerative, Anti-Asthmatic, Anti Bacterial, etc. The firm has 2 units and to set up a second plant for which they took a loan from Bank but did not get the clearance due to the vested interest of the local government. It took 26 months to get clearance from the Local government. At the same time, an untimely separate state agitation happened and non-co-operation from banks led to the company becoming NPA. That's why sales are 0.
 Capital Requirement
|
INR 350 to 400 Mn |
| Justification: The firm has large domestic and international clients including Pfizer, Ranbaxy, Dr. Reddy, etc. | |
|
Funding Route
Private Equity, Strategic Investor |
Extent Of Dilution
Upto 49 % |
|
Share Holding Pattern
Promoter Group 100% Non-Promoter Share Holder 0% |
Reason For Raising Capital
Reduce Leverage, |
| Entity is open for Investor keen on special situation/distress assets funding. | |
Industry: Pharmaceuticals
Sub-Industry: Bulk Drug manufacturing
Division
Division`s Buyers/Customers
Division`s Plant Location
Justification n/a
Justification n/a
| 2017 (in INR) | 2018 (in INR) | 2019 (in INR) | 2020 (in INR) | ||
|---|---|---|---|---|---|
| Sales | N.D | N.D | N.D | N.D | |
| EBDITA | N.D | N.D | N.D | N.D | |
| PAT | N.D | N.D | N.D | N.D | |
| TANGIBLE NET WORTH | N.D | N.D | N.D | N.D | |
| LONG TERM DEBT | N.D | N.D | N.D | N.D | |
| TOTAL DEBT | N.D | N.D | N.D | N.D | |
If you are interested in connecting with business please send an Expression of Interest.
EXPRESS INTEREST MARK FAVOURITE
